INTERNATIONAL PATENT: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. FILES APPLICATION FOR "ANTI-CANCER DRUGS BASED ON SYNTHETIC LETHAL INTERACTIONS WITH TP53 OR MLH1 MUTATIONS"

GENEVA, March 9 -- YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (Hi-Tech Park, Edmond J. Safra CampusGivat Ram, P.O.B. 3913591390 Jerusalem) filed a patent application (PCT/IL2025/050728) for "ANTI-CANCER DRUGS BASED ON SYNTHETIC LETHAL INTERACTIONS WITH TP53 OR MLH1 MUTATIONS" on Aug 27, 2025. With publication no. WO/2026/047668, the details related to the patent application was published on Mar 05, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): BENVENISTY, Nissim (83 Herzel Blvd.9634402 Jerusalem), KOPPER, Oded (Moshe Lerer 24/167404963 Ness-Ziona), CASHM...